Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec

Posted: July 11, 2024 at 2:43 am

Bagsværd, Denmark, 10 July 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus.

See more here:
Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec

Related Posts